Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ianalumab - MorphoSys/Novartis

Drug Profile

Ianalumab - MorphoSys/Novartis

Alternative Names: NOV-5; VAY-736

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys; Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; MorphoSys; Novartis
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; B-cell activation factor receptor modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Autoimmune hepatitis
  • Phase II Idiopathic pulmonary fibrosis; Multiple sclerosis; Pemphigus vulgaris; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
  • Phase I Chronic lymphocytic leukaemia

Most Recent Events

  • 25 Oct 2019 Novartis terminates a phase II trial in Multiple sclerosis in USA, Ukraine, Poland and Czech Republic based on strategic considerations after eight patients were enrolled (IV) (NCT02038049)
  • 25 Sep 2019 Novartis completes a phase II trial in Pemphigus vulgaris in USA, Austria, Bulgaria and Taiwan (NCT01930175)
  • 31 Dec 2018 Novartis announces intention to submit regulatory applications for Autoimmune hepatitis in or after 2023 (Novartis pipeline, March 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top